How Targeted Cancer Drugs Disrupt the Cell Cycle
PLOS: DNA Science
JUNE 22, 2023
The candidate drug, vorasidenib, is a small molecule that inhibits survivin. Gleevec came from a massive effort throughout the 1980s to screen more than 400 small molecules for one that would block the activity of the errant tyrosine kinase, without derailing other important enzymes. It is a cyclin-dependent kinase.
52 
Let's personalize your content